 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...123124125126127128129130131132133...143144» |
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1 trial: Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - May 8, 2015
P1, N=21, Not yet recruiting, Sponsor: North Shore Long Island Jewish Health System
- gedatolisib (PF-05212384) / Celcuity
Enrollment change, Metastases: A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer (clinicaltrials.gov) - May 5, 2015
P2, N=150, Terminated, Sponsor: Pfizer
N=17 --> 150
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Kisqali (ribociclib) / Novartis
New P1 trial, Metastases: CETLEE011: Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck (clinicaltrials.gov) - Apr 30, 2015
P1, N=26, Recruiting, Sponsor: Cliniques universitaires Saint-Luc- Universit
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial primary completion date: Treatment Regimens for Patients With Resectable Liver Metastases (PANTER Study) (clinicaltrials.gov) - Apr 30, 2015
P=N/A, N=430, Active, not recruiting, Sponsor: RWTH Aachen University
N=17 --> 150 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> May 2015
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Enrollment open, Combination therapy, Metastases: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov) - Apr 25, 2015
P1, N=216, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> May 2015 Active, not recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer (clinicaltrials.gov) - Apr 25, 2015
P2, N=15, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA (clinicaltrials.gov) - Apr 22, 2015
P1, N=30, Recruiting, Sponsor: North Shore Long Island Jewish Health System
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2013 --> Dec 2017
- ||| cixutumumab (IMC A12) / Eli Lilly, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Enrollment closed: Preoperative Treatment With Cetuximab and/or IMC-A12 (clinicaltrials.gov) - Apr 22, 2015
P2, N=60, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2013 --> Dec 2017 Recruiting --> Active, not recruiting
- |||| Opdivo (nivolumab) / BMS
Trial primary completion date, Metastases: Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) (clinicaltrials.gov) - Apr 21, 2015
P3, N=360, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2016 --> Oct 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Gilotrif (afatinib) / Boehringer Ingelheim
Trial primary completion date, Metastases: Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 19, 2015
P2, N=75, Recruiting, Sponsor: UNICANCER
Trial primary completion date: Jun 2016 --> Oct 2016 Trial primary completion date: Oct 2014 --> Jul 2015
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: METHEP-2: Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases (clinicaltrials.gov) - Apr 19, 2015
P2, N=256, Recruiting, Sponsor: UNICANCER
Trial primary completion date: Oct 2014 --> Jul 2015 Trial primary completion date: Feb 2014 --> May 2016
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab (clinicaltrials.gov) - Apr 19, 2015
P2, N=132, Recruiting, Sponsor: UNICANCER
Trial primary completion date: Feb 2014 --> May 2016 Trial primary completion date: Dec 2013 --> Jun 2015
- EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
Trial primary completion date, IO biomarker, Metastases: Anti-CD3 x Anti-Erbitux (clinicaltrials.gov) - Apr 19, 2015
P1, N=30, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Trial primary completion date: Dec 2013 --> Jun 2015 Trial primary completion date: Feb 2015 --> Jul 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Trial primary completion date: Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab (clinicaltrials.gov) - Apr 19, 2015
P=N/A, N=40, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Feb 2015 --> Jul 2015 Trial primary completion date: Dec 2014 --> Dec 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) - Apr 19, 2015
P2, N=41, Recruiting, Sponsor: Hong Kong Nasopharyngeal Cancer Study Group Limited
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: May 2013 --> Dec 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: MACRO-2: Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours (clinicaltrials.gov) - Apr 19, 2015
P2, N=194, Active, not recruiting, Sponsor: Spanish Cooperative Group for Digestive Tumour Therapy (TTD)
Trial primary completion date: May 2013 --> Dec 2016 Trial primary completion date: Jul 2014 --> May 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: TACETUX: Observational Study on Second Line Treatment of Liver Metastases With DEBIRI and Cetuximab (clinicaltrials.gov) - Apr 16, 2015
P=N/A, N=40, Recruiting, Sponsor: International Group of Endovascular Oncology
Trial primary completion date: Jul 2014 --> May 2015 Trial primary completion date: May 2014 --> May 2016
- |||||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) (clinicaltrials.gov) - Apr 16, 2015
P3, N=750, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: May 2014 --> May 2016 Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2018 --> Nov 2017
- || prexasertib (ACR-368) / Acrivon Therap
Trial primary completion date, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Apr 14, 2015
P1, N=70, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2018 --> Nov 2017 Trial primary completion date: Oct 2017 --> Jun 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer (clinicaltrials.gov) - Apr 14, 2015
P2, N=54, Recruiting, Sponsor: Tianshu Liu
Trial primary completion date: Oct 2017 --> Jun 2016 Trial primary completion date: Feb 2015 --> Feb 2016
- ||| Biomarker, Trial initiation date, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker, Metastases: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Apr 14, 2015
P2, N=610, Not yet recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Feb 2015 --> Feb 2016 Initiation date: Apr 2015 --> Jan 2015 | Trial primary completion date: May 2019 --> Nov 2020
- Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change: PD 0332991 and Cetuximab in Patients With Incurable SCCHN (clinicaltrials.gov) - Apr 14, 2015
P1/2, N=72, Recruiting, Sponsor: Washington University School of Medicine
Initiation date: Apr 2015 --> Jan 2015 | Trial primary completion date: May 2019 --> Nov 2020 N=42 --> 72
- AlloStim (bioengineered allogeneic immune cells) / Immunovative
Enrollment change, Trial withdrawal, Metastases: AlloStim (clinicaltrials.gov) - Apr 14, 2015
P2/3, N=0, Withdrawn, Sponsor: Immunovative Therapies, Ltd.
N=42 --> 72 N=208 --> 0 | Not yet recruiting --> Withdrawn
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Combination therapy, Metastases: Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Apr 14, 2015
P2, N=112, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
N=208 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Dec 2014 --> Dec 2016
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 13, 2015
P2, N=70, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2014 --> Dec 2016 No longer recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Enrollment change, Trial primary completion date, Metastases: Cetuximab Zr89: Non-invasive Imaging of Cetuximab-Zr. 89 Uptake Wit PET: a Phase I Trial in Stage IV Cancer Patients (clinicaltrials.gov) - Apr 10, 2015
P1, N=9, Completed, Sponsor: Maastricht Radiation Oncology
No longer recruiting --> Completed Recruiting --> Completed | N=12 --> 9 | Trial primary completion date: Dec 2014 --> Mar 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: A Trial of Chemo & Radiation Therapy for Pancreatic Cancer (clinicaltrials.gov) - Apr 8, 2015
P2, N=8, Completed, Sponsor: University of Massachusetts, Worcester
Recruiting --> Completed | N=12 --> 9 | Trial primary completion date: Dec 2014 --> Mar 2015 Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Enrollment closed, Combination therapy, Metastases: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov) - Apr 6, 2015
P1, N=216, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| REGN1400 / Regeneron
Trial completion, Combination therapy: Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer (clinicaltrials.gov) - Apr 6, 2015
P1, N=56, Completed, Sponsor: Regeneron Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Perjeta (pertuzumab) / Roche
Trial completion, Combination therapy, Metastases: Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 2, 2015
P1/2, N=17, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Terminated --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: TIME-PRODIGE 28 UNICANCER: Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC) (clinicaltrials.gov) - Apr 1, 2015
P2, N=136, Recruiting, Sponsor: UNICANCER
- Halaven (eribulin mesylate) / Eisai, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial primary completion date, Metastases: A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer (clinicaltrials.gov) - Mar 31, 2015
P1/2, N=63, Active, not recruiting, Sponsor: howard safran
Terminated --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Mar 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Enrollment change: PGx-SELECT: Study Using Pharmacogenetics to Select Treatment for Head and Neck Cancer (clinicaltrials.gov) - Mar 27, 2015
P2, N=0, Withdrawn, Sponsor: Georgetown University
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Mar 2015 N=96 --> 0
- Leukine (sargramostim) / Partner Therap, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial termination, IO biomarker, Metastases: Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors (clinicaltrials.gov) - Mar 25, 2015
P1, N=2, Terminated, Sponsor: Roger Williams Medical Center
N=96 --> 0 N=16 --> 2 | Recruiting --> Terminated; Funding ended
- Leukine (sargramostim) / Partner Therap, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial termination, Trial primary completion date, IO biomarker, Metastases: Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Mar 25, 2015
P1, N=5, Terminated, Sponsor: Roger Williams Medical Center
N=16 --> 2 | Recruiting --> Terminated; Funding ended N=24 --> 5 | Recruiting --> Terminated | Trial primary completion date: May 2015 --> Dec 2014; Funding ended
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: GORTEC 2009-01: Trial of OTD70DERM® in Radio-dermatitis Induced by Radiotherapy-Erbitux® (clinicaltrials.gov) - Mar 24, 2015
P3, N=76, Completed, Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
N=24 --> 5 | Recruiting --> Terminated | Trial primary completion date: May 2015 --> Dec 2014; Funding ended Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver (clinicaltrials.gov) - Mar 24, 2015
P2, N=20, Completed, Sponsor: NSABP Foundation Inc
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer (clinicaltrials.gov) - Mar 18, 2015
P2, N=41, Completed, Sponsor: Hoosier Cancer Research Network
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-Cetuximab (clinicaltrials.gov) - Mar 17, 2015
P=N/A, N=40, Active, not recruiting, Sponsor: Sofia Perea, Director Clinical Trials Unit.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer (clinicaltrials.gov) - Mar 14, 2015
P2, N=13, Terminated, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2014 --> Aug 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Enrollment closed, Trial initiation date, Trial primary completion date, Metastases: Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab (clinicaltrials.gov) - Mar 12, 2015
P2, N=80, Active, not recruiting, Sponsor: Academic and Community Cancer Research United
Trial primary completion date: Aug 2014 --> Aug 2015 Recruiting --> Active, not recruiting | Initiation date: Apr 2013 --> Aug 2012 | Trial primary completion date: Aug 2014 --> Dec 2015
- Erbitux (cetuximab) / Eli Lilly, Zelboraf (vemurafenib) / Roche
Trial primary completion date, Combination therapy, Surgery, Metastases: Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery (clinicaltrials.gov) - Mar 12, 2015
P1, N=77, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | Initiation date: Apr 2013 --> Aug 2012 | Trial primary completion date: Aug 2014 --> Dec 2015 Trial primary completion date: Feb 2016 --> Feb 2017
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date, Metastases: AGMT_HNO_PN: Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck (clinicaltrials.gov) - Mar 12, 2015
P3, N=146, Not yet recruiting, Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Trial primary completion date: Feb 2016 --> Feb 2017 Initiation date: Jan 2015 --> Jun 2015
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Trial initiation date, Surgery, Metastases: BOND-3: Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Mar 12, 2015
P2, N=120, Recruiting, Sponsor: Academic and Community Cancer Research United
Initiation date: Jan 2015 --> Jun 2015 Not yet recruiting --> Recruiting | Initiation date: Dec 2014 --> Mar 2015
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Enrollment change, Metastases: MACBETH: Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient (clinicaltrials.gov) - Mar 12, 2015
P2, N=143, Completed, Sponsor: Gruppo Oncologico del Nord-Ovest
Not yet recruiting --> Recruiting | Initiation date: Dec 2014 --> Mar 2015 Recruiting --> Completed | N=106 --> 143
- ||| Biomarker, Trial initiation date, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker, Metastases: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Mar 10, 2015
P2, N=610, Not yet recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed | N=106 --> 143 Initiation date: Jan 2015 --> Apr 2015 | Trial primary completion date: Nov 2020 --> May 2019
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P3 trial, Combination therapy, Metastases: CHANGE2: Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer (clinicaltrials.gov) - Mar 10, 2015
P3, N=240, Not yet recruiting, Sponsor: Merck KGaA
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Pharmacokinetics and Metabolic Activation of Capecitabine (clinicaltrials.gov) - Mar 9, 2015
P2, N=24, Completed, Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Initiation date: Jan 2015 --> Apr 2015 | Trial primary completion date: Nov 2020 --> May 2019 Active, not recruiting --> Completed
- |||| Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) (clinicaltrials.gov) - Mar 8, 2015
P3, N=750, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Trial primary completion date: Aug 2017 --> Jun 2018
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, motolimod (VTX 2337) / BMS
Trial completion, Combination therapy, Metastases: TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck (clinicaltrials.gov) - Mar 7, 2015
P1, N=13, Completed, Sponsor: University of Washington
Trial primary completion date: Aug 2017 --> Jun 2018 Active, not recruiting --> Completed